Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA

Table 1 Comparison of value estimates obtained in tests and re-tests^a, by weighting technique, comparator and country

Comparator	Weighting technique	France		Italy		Spain
Comparator	Weighting technique	Mean test (SD)	Mean re-test (SD)	Mean test (SD)	Mean re-test (SD)	Mean test (SD)	Mean re-test (SD)
vs watchful waiting	5-point weighting scale	0.22 (0.14)	0.32 (0.13)	0.33 (0.14)	0.31 (0.10)	0.30 (0.11)	0.29 (0.07)
	5-point weighting scale	ICC (3,1) = 0.732		ICC (3,1) = 0.511		ICC (3,1) = 0.628
	Hierarchical point allocation	0.24 (0.13)	0.33 (0.17)	0.34 (0.15)	0.36 (0.20)	0.38 (0.20)	0.31 (0.15)
	Hierarchical point allocation	ICC (3,1) = 0.913		ICC (3,1) = 0.668		ICC (3,1) = 0.877
vs sorafenib	5-point weighting scale	0.31 (0.14)	0.29 (0.11)	0.35 (0.16)	0.34 (0.12)	0.36 (0.11)	0.31 (0.09)
	5-point weighting scale	ICC (3,1) = 0.832		ICC (3,1) = 0.437		ICC (3,1) = 0.724
	Hierarchical point allocation	0.32 (0.16)	0.30 (0.18)	0.37 (0.15)	0.36 (0.20)	0.41 (0.18)	0.33 (0.15)
	Hierarchical point allocation	ICC (3,1) = 0.772		ICC (3,1) = 0.649		ICC (3,1) = 0.865

ICC intra-rater correlation coefficient, SD standard deviation
^aTest-retest data were available for 5 panelists from France, 7 from Italy and 7 from Spain

ISSN: 1471-2407